Biosynthesis Almost all animal tissues synthesize cholesterol from
acetyl-CoA. All animal cells (with some exceptions within the invertebrates) manufacture cholesterol, for both membrane structure and other uses, with relative production rates varying by cell type and organ function. About 80% of total daily cholesterol production occurs in the
liver and the
intestines; other sites of higher
synthesis rates include the
brain, the
adrenal glands, and the
reproductive organs. Synthesis within the body starts with the
mevalonate pathway where two molecules of acetyl-CoA condense to form
acetoacetyl-CoA. This is followed by a second condensation between acetyl-CoA and acetoacetyl-CoA to form
3-hydroxy-3-methylglutaryl CoA (
HMG-CoA). This molecule is then reduced to
mevalonate by the enzyme
HMG-CoA reductase. Production of mevalonate is the rate-limiting and irreversible step in cholesterol synthesis and is the site of action for
statins (a class of cholesterol-lowering drugs). Mevalonate is finally converted to
isopentenyl pyrophosphate (IPP) through two phosphorylation steps and one decarboxylation step that requires
ATP. Three molecules of isopentenyl pyrophosphate condense to form
farnesyl pyrophosphate through the action of geranyl transferase. Two molecules of farnesyl pyrophosphate then condense to form
squalene by the action of
squalene synthase in the
endoplasmic reticulum. The final 19 steps to cholesterol contain
NADPH and oxygen to help oxidize
methyl groups for the removal of carbons,
mutases to move
alkene groups, and
NADH to help reduce
ketones.
Konrad Bloch and
Feodor Lynen shared the
Nobel Prize in Physiology or Medicine in 1964 for their discoveries concerning some of the mechanisms and methods of regulation of cholesterol and
fatty acid metabolism.
Regulation of cholesterol synthesis Biosynthesis of cholesterol is directly regulated by the cholesterol levels present, though the
homeostatic mechanisms involved are only partly understood. A higher intake of food leads to a net decrease in endogenous production, whereas a lower intake of food has the opposite effect. The main regulatory mechanism is the sensing of
intracellular cholesterol in the
endoplasmic reticulum by the
protein SREBP (sterol regulatory element-binding protein 1 and 2). In the presence of cholesterol, SREBP is bound to two other proteins:
SCAP (SREBP cleavage-activating protein) and
INSIG-1. When cholesterol levels fall, INSIG-1 dissociates from the SREBP-SCAP complex, which allows the complex to migrate to the
Golgi apparatus. Here SREBP is cleaved by S1P and S2P (site-1 protease and site-2 protease), two enzymes that are activated by SCAP when cholesterol levels are low. The cleaved SREBP then migrates to the nucleus and acts as a
transcription factor to bind to the sterol regulatory element (SRE), which stimulates the
transcription of many genes. Among these are the low-density lipoprotein (
LDL) receptor and
HMG-CoA reductase. The LDL receptor scavenges circulating LDL from the bloodstream, whereas HMG-CoA reductase leads to an increase in endogenous production of cholesterol. A large part of this signaling pathway was clarified by Dr.
Michael S. Brown and Dr.
Joseph L. Goldstein in the 1970s. In 1985, they received the
Nobel Prize in Physiology or Medicine for their work. Their subsequent work shows how the SREBP pathway regulates the expression of many genes that control lipid formation and metabolism and body fuel allocation. Cholesterol synthesis can be turned off when cholesterol levels are high. HMG-CoA reductase contains both a cytosolic domain (responsible for its catalytic function) and a membrane domain which senses signals for its degradation. Increasing concentrations of cholesterol (and other sterols) cause a change in this domain's oligomerization state, making it more susceptible to destruction by the
proteasome. This enzyme's activity can also be reduced by phosphorylation by an AMP-activated protein
kinase. Because this kinase is activated by AMP, which is produced when ATP is hydrolyzed, it follows that cholesterol synthesis is halted when ATP levels are low.
Plasma transport and regulation of absorption As an isolated molecule, cholesterol is only minimally soluble in
water, or
hydrophilic. Because of this, it dissolves in blood at exceedingly small concentrations. To be transported effectively, cholesterol is instead packaged within
lipoproteins, complex
discoidal particles with exterior
amphiphilic proteins and lipids, whose outward-facing surfaces are water-soluble and inward-facing surfaces are lipid-soluble. This allows it to travel through the blood via
emulsification. Unbound cholesterol, also being amphiphilic, is transported in the monolayer surface of the lipoprotein particle along with phospholipids and proteins. Cholesterol esters bound to fatty acid, on the other hand, are transported within the fatty hydrophobic core of the lipoprotein, along with triglyceride. There are several types of lipoproteins in the blood. In order of increasing density, they are
chylomicrons,
very-low-density lipoprotein (VLDL),
intermediate-density lipoprotein (IDL),
low-density lipoprotein (LDL), and
high-density lipoprotein (HDL). Lower protein/lipid ratios make for less dense lipoproteins. Cholesterol within different lipoproteins is identical, although some are carried as their native "free" alcohol form (the cholesterol-OH group facing the water surrounding the particles), while others as fatty acyl esters (known also as cholesterol esters) within the particles. in their shells. Chylomicrons carry fats from the intestine to muscle and other tissues in need of fatty acids for energy or fat production. Unused cholesterol remains in more cholesterol-rich chylomicron remnants and is taken up from here to the bloodstream by the liver. These plaques are the main causes of heart attacks, strokes, and other serious medical problems, leading to the association of so-called LDL cholesterol (actually a
lipoprotein) with the term "bad" cholesterol. Large numbers of HDL particles correlates with better health outcomes, whereas low numbers of HDL particles is associated with
atheromatous disease progression in the arteries.
Metabolism, recycling and excretion Cholesterol is susceptible to oxidation and easily forms oxygenated derivatives called
oxysterols. These can be formed by three different mechanisms: autoxidation, secondary oxidation to lipid peroxidation, and cholesterol-metabolizing enzyme oxidation. A great interest in oxysterols arose when they were shown to exert inhibitory actions on cholesterol biosynthesis. This finding became known as the "oxysterol hypothesis". Additional roles for oxysterols in human physiology include their participation in bile acid biosynthesis, function as transport forms of cholesterol, and regulation of gene transcription. In biochemical experiments, radiolabelled forms of cholesterol, such as tritiated-cholesterol, are used. These derivatives undergo degradation upon storage, and it is essential to purify cholesterol prior to use. Cholesterol can be purified using small Sephadex LH-20 columns. Cholesterol is oxidized by the liver into a variety of
bile acids. These, in turn, are
conjugated with
glycine,
taurine,
glucuronic acid, or
sulfate. A mixture of conjugated and nonconjugated bile acids, along with cholesterol itself, is excreted from the
liver into the
bile. Approximately 95% of the bile acids are reabsorbed from the intestines, and the remainder are lost in the feces. The excretion and reabsorption of bile acids forms the basis of the
enterohepatic circulation, which is essential for the digestion and absorption of dietary fats. Under certain circumstances, when more concentrated, as in the
gallbladder, cholesterol crystallises and is the major constituent of most
gallstones (
lecithin and
bilirubin gallstones also occur, but less frequently). Every day, up to one gram of cholesterol enters the colon. This cholesterol originates from the diet, bile, and desquamated intestinal cells, and it can be metabolized by the colonic bacteria. Cholesterol is converted mainly into
coprostanol, a nonabsorbable sterol that is excreted in the feces. Although cholesterol is a steroid generally associated with mammals, the human pathogen
Mycobacterium tuberculosis is able to completely degrade this molecule and contains a large number of genes that are regulated by its presence. Many of these cholesterol-regulated genes are
homologues of
fatty acid β-oxidation genes, which have evolved in such a way as to bind large steroid substrates like cholesterol. ==Dietary sources==